Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871377 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
A Phase 2 study of Epilepsy, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00871377: Completed Phase 2 study of Epilepsy, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00871377 is a Phase 2 study of Epilepsy that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 24 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00871377, a Phase 2 study of Epilepsy, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
Primary Outcome
Seizure frequency (seizures per day or seizures per month)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG High Dose Fish Oil
- DRUG Low Dose Fish Oil
Study Locations (1)
California
- UCLA General Clinical Research Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00871377 record still lists
NCT00871377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00871377 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00871377 about?
NCT00871377 is a clinical study titled "Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures". The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
What is the current status of trial NCT00871377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-05. Estimated completion is 2011-08.
What conditions does trial NCT00871377 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00871377?
The interventions under investigation include: Placebo (DRUG), High Dose Fish Oil (DRUG), Low Dose Fish Oil (DRUG).
Who is sponsoring clinical trial NCT00871377?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00871377 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00871377's enrollment target sits among peer trials
24 123rd of 160 higher than 32 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia